Bone Biologics (BBLG) Projected to Announce Quarterly Earnings on Thursday

Bone Biologics (NASDAQ:BBLG) is expected to be announcing its results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.39) per share for the quarter.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). On average, analysts expect Bone Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Bone Biologics Trading Down 5.7%

Bone Biologics stock opened at $0.88 on Tuesday. Bone Biologics has a 1-year low of $0.83 and a 1-year high of $4.13. The firm has a market capitalization of $1.59 million, a PE ratio of -0.39 and a beta of 0.93. The firm’s 50 day simple moving average is $1.22 and its 200 day simple moving average is $1.27.

Hedge Funds Weigh In On Bone Biologics

A hedge fund recently raised its position in Bone Biologics stock. DRW Securities LLC grew its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned approximately 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.